SENS.L Regulatory News (SENS)

Sensyne Health

("Sensyne", the "Company" or the "Group")

Sensyne Health settles employment tribunal claim

Oxford, U.K. 10 August 2020: Sensyne Health plc (LSE: SENS), the Clinical AI technology company, today issues a statement regarding the settlement of an employment tribunal claim.

As previously announced, Lorimer Headley, left the Board and the business on 2 March 2020. He made allegations against the CEO, Lord Drayson. The Board arranged for these allegations to be investigated by an independent law firm and they found that the allegations were not supported by the evidence. The Board has decided, to avoid further legal costs and distraction for the business and in recognition of Mr Headley's contribution to Sensyne Health, to make a payment as compensation for loss of office to Mr Headley of £150,000 and a contribution of £200,000 towards his legal fees. As part of that settlement the Board has also agreed to provide outplacement assistance up to a value of £30,000. This constitutes full and final settlement of all claims in relation to his employment.

Following termination of his employment, Mr Headley also received a payment in lieu of his three-month contractual notice period and a payment in lieu of accrued but untaken holiday.

The compensation payment to Mr Headley constitutes a 'related party transaction' pursuant to Rule 13 of the AIM Rules for Companies. The directors consider, having consulted with Peel Hunt, the Company's nominated adviser, that the terms of the settlement are fair and reasonable insofar as shareholders are concerned.

-ENDS-

For more information please contact:

About Sensyne Health 

Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

For more information, please visit: www.sensynehealth.com